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Background: Immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in
pregnancy is increasingly recommended. We determined the effect of Tdap immunization
in pregnancy on infants’ vaccine responses.
Methods: Individual-participant data meta-analysis of ten studies (n=1884) investigating
infants’ antibody response to routine immunizations following Tdap immunization in
pregnancy was performed. Geometric mean ratios (GMRs) of antigen-specific
immunoglobulin G (IgG) levels were calculated using mixed-effects models.
Seroprotection rates were compared using chi-squared tests.
Results: Infants of Tdap-immunized women had significantly lower IgG against pertussis
toxin (GMR 0.65; 95%CI 0.57-0.74), filamentous haemagglutinin (FHA) (0.68; 0.53-0.87),
pertactin (0.65; 0.58-0.72) and fimbria 2/3 (FIM2/3) (0.41; 0.32-0.52) after primary
immunization, compared with infants of unimmunized women. These lower levels
persisted after booster immunization for FHA (0.72; 0.61-0.84) and FIM2/3 (0.53; 0.29-
0.96). After primary immunization, infants of Tdap-immunized women had lower
seroprotection rates against diphtheria (90% [843/973] vs 98% [566/579]; p<0.001)
and invasive pneumococcal disease (IPD) caused by 5 Streptococcus pneumoniae (SPN)org July 2021 | Volume 12 | Article 6893941
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Frontiers in Immunology | www.frontiersin.serotypes (SPN5, SPN6B, SPN9V, SPN19A, SPN23F), and higher seroprotection rates
against Haemophilus influenzae type b (short-term and long-term seroprotection rates,
86%[471/547] vs 76%[188/247] and 62%[337/547] vs 49%(121/247), respectively, all
p=0.001). After booster immunization, seroprotection rates against diphtheria and tetanus
were 99% (286/288) and (618/619) in infants of Tdap-immunized women, respectively.
Conclusions: Infants of Tdap-immunized women in pregnancy had lower IgG levels
against pertussis, diphtheria and some SPN serotypes after their immunization compared
with infants of unimmunized women. Enhanced surveillance of pertussis, diphtheria and
IPD in infants is needed to determine the clinical significance of these findings.
Systematic Review Registration: CRD42017079171.Keywords: pertussis, immunization, pregnancy, infants, gestationalINTRODUCTION
Pertussis disease is caused in humans mainly by Bordetella
pertussis, a gram-negative, aerobic coccobacillus bacterium (1).
Clinical manifestations are divided into three classical stages:
catarrhal, paroxysmal and convalescent. The catarrhal stage is an
influenza-like disease with low-grade fever, malaise, nasal
congestion, rhinorrhea, sneezing and mild cough. The
paroxysmal stage is characterized by the classical “whooping
cough” [many violent and rapid coughs followed by a high-pitch
“whoop” voice (1)], which might be associated with vomiting.
The convalescent stage is characterized by a decrease in
paroxysmal cough frequency. Each stage lasts ~1-3 weeks (1).
Pertussis is most severe in youngest infants leading to substantial
morbidity and mortality (2, 3). Infants with pertussis can have
severe complications such as apnea, seizures [reported in 3% of
infants <30 days (4)].
Current infants’ and adults’ immunization programs in most
high-income countries use acellular pertussis (aP) vaccines in their
schedules. The aP vaccines are composed of purified bacterial
antigens (pertussis toxin [PT], filamentous hemagglutinin [FHA],
pertactin [PRN], and some aP vaccines has alsofimbriae [FIM2/3]).
Immunization with tetanus-diphtheria-acellular pertussis
(Tdap) vaccine in pregnancy has been implemented in an
increasing number of countries leading to successful reduction
in pertussis incidence, morbidity and mortality in young infants
(5–7). While the mechanism of protection via immunization in
pregnancy has not been established, it is mediated, at least in
part, by increasing anti-B. pertussis antibodies in the newborn (8,
9). Early studies in infants born to women not immunized in
pregnancy suggested that higher pre-existing maternally derived
antibody levels could have a suppressive effect on infants’ active
immune responses to their own immunizations leading to low
post-immunization antibody levels (10–13). Later studies in
infants born to women immunized with Tdap in pregnancy
showed modification of immune responses to immunizations in
infancy, leading to lower antibody levels in infants born to
women immunized with Tdap compared with infants born to
women unimmunized in pregnancy (8, 14–16). However, data
are conflicting regarding the antigen-specific antibodies affected,org 2the degree, quantity and the duration of such modifications in
immune responses.
While the focus of these analyses has been on pertussis-specific
antibody responses, Tdap vaccines administered in pregnancy
also include tetanus and diphtheria antigens – which may thus
influence responses to the same antigens in infants, as well as
protein-polysaccharide conjugate vaccines (such as Haemophilus
influenzae type b [Hib] and pneumococcal) which include these
antigens as carrier proteins. Data are lacking on whether these
immune effects translate into lower seroprotection rates for
diseases in which correlates of protection exist (tetanus,
diphtheria, Hib and invasive pneumococcal disease [IPD]). The
aim of this study was to determine how Tdap immunization in
pregnancy modifies infants’ antibody response to their own
routine primary and booster immunizations and affects
seroprotection rates.METHODS
Search Strategy and Selection Criteria
This study followed Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) for Individual-Patient
Data reporting guidelines (Supplementary Table 1) (17).
PubMed, MEDLINE, Embase, Cumulative Index to Nursing
and Allied Health Literature (CINAHL), and the Cochrane
Central Register of Controlled Trials (CENTRAL) databases
were searched for English literature reporting immunoglobulin
G (IgG) levels following primary and booster immunizations in
infants born to women immunized against pertussis in
pregnancy and infants of women unimmunized in pregnancy,
published between January 1st, 1990 and January 6th, 2020
(Supplementary Methods).
Studies were included if they:
1) Measured IgG levels to at least one of the following antigens –
PT, FHA, PRN, FIM2/3, tetanus-toxoid [TT], diphtheria-toxoid
[DT]), Hib polyribosyl ribitol phosphate (PRP), Neisseria
meningitidis or Streptococcus pneumoniae (SPN) – in infants
post-primary and/or post-booster (at age 9-24 months)July 2021 | Volume 12 | Article 689394
Abu-Raya et al. Immune Responses to Immunizationsimmunizat ions with diphtheria-tetanus-acel lular
pertussis (DTaP), Hib, meningococcal conjugate and/or
pneumococcal conjugate vaccines (PCV).
2) Reported these IgG levels for infants born at ≥36 weeks
gestation (WG) to women immunized at any time in
pregnancy with a single dose of Tdap vaccine and for
infants born at ≥36 WG to women unimmunized with
Tdap in pregnancy in the same study (the use of TT or
diphtheria and tetanus toxoids (dT) vaccines in pregnancy as
a control to Tdap immunization in pregnancy was allowed).
Studies were excluded if they:
1) Included only infants <36 WG;
2) Included only infants or women with an immunologic
disorder;
3) Included only infants who received immunoglobulins in the
previous year before antibody response assessment;
4) Included only women who received immunosuppressive drugs
during the current pregnancy, blood products 3 months prior
to delivery, intravenous immunoglobulins within the previous
year before delivery, immunosuppressive drugs or blood
products 3 months prior to antibody response assessment in
the women.
Authors of the identified studies were contacted to share
individual-participant data for the meta-analysis.
Data Analysis
An individual-participant data meta-analysis of anti-B. pertussis
antibody levels in infants of women immunized with Tdap in
pregnancy compared with infants of women unimmunized with
Tdap in pregnancy was done. Anti-FIM2/3 antibody analyses
were restricted to women and infants who received FIM2/3-
containing vaccines in pregnancy and in infancy, respectively.
For anti-TT and anti-PRP antibody analyses, women
unimmunized with Tdap but immunized with TT or dT in
pregnancy were excluded from analyses, as well their infants. For
anti-DT and anti-SPN antibody analyses, women unimmunized
with Tdap but immunized with dT in pregnancy were excluded
from analyses, as well their infants.
In order to ensure individual-participant data integrity, data
received were recapitulated for each study for main baseline
characteristics and IgG levels and compared with numbers of
participants and data reported by the authors.
IgG levels were log2-transformed and meta-analyzed using
mixed-effects models for each antigen-specific antibody and time
point with study site and primary vaccination schedule as
random intercepts. The main time points were post-primary
and post-booster immunization in infants. Additional analysis
time points were: pre-immunization in pregnancy, post-
immunization in pregnancy (4 weeks after immunization in
pregnancy), at delivery (maternal and cord blood), pre-primary
immunization and pre-booster immunization. The mixed-effects
models included co-variates known to influence immune
responses to immunization and were available within the
datasets (18). For the maternal time points and infants’ timeFrontiers in Immunology | www.frontiersin.org 3points pre-primary immunization, adjustment was made for
maternal age at immunization and pre-existing homologous
antibody levels. For the infants’ post-primary, pre-booster and
post-booster immunization time points, adjustment was made
for infant sex and infant age at primary immunization.
The antilog (2x) of the coefficients from the models and their
95% confidence intervals (CIs) were presented as geometric
mean ratios (GMRs) and their 95% CIs. For maternal time
points, the GMR was interpreted as the ratio of antigen-
specific IgG levels in women immunized with Tdap in
pregnancy versus levels in women unimmunized in pregnancy.
For infants’ time points, the GMR was interpreted as the ratio of
antigen-specific IgG levels in infants born to women immunized
with Tdap in pregnancy versus levels in infants of women
unimmunized in pregnancy.
Seroprotection rates against tetanus disease (anti-TT IgG
≥0.1 IU/mL), diphtheria disease (anti-DT IgG ≥0.1 IU/mL),
IPD (anti-SPN IgG ≥0.35 mg/mL), Hib disease (anti-PRP IgG
≥0.15 µg/ml and anti-PRP IgG ≥1 µg/ml for short- and long-
term protection, respectively) were calculated (19). A chi-squared
test was used to determine whether the seroprotection rates were
different among women immunized with Tdap in pregnancy
compared with unimmunized women, and in infants born to
women immunized with Tdap in pregnancy compared with
infants of unimmunized women.
Risk of bias of randomized-controlled trials was assessed against
the Cochrane Risk of Bias tool for randomized-controlled trials.
Riskofbias ofnon-randomized studieswas assessedusingROBIN-I
tool (20). Risk of bias was assessed by two independent researchers
(Bahaa Abu-Raya and Kirsten Maertens).
R version 3.4.0 was used for all analysis (meta package, version
4.9-1). The study was registered at The International prospective
register of systematic reviews PROSPERO (CRD42017079171).ROLE OF THE FUNDING SOURCE
The funders had no role in the design, analysis or interpretation
of the results.RESULTS
A total of 8391 articles were screened and 72 full-text articles
were assessed for eligibility. Sixteen articles met the inclusion
criteria, which originated from 12 studies (some studies that
included post-primary and post-booster immunization
assessment were published in separate and sequential articles
leading to higher number of published articles than the number
of original articles) (Figure 1). All but one of the studies were
done in high-income countries and 1 study in a middle-income
country (Table 1). Women who did not receive Tdap in
pregnancy were unimmunized or given placebo in 10/12
studies (8, 14, 15, 21–23, 25, 26, 28–32), given TT in 1/12
study (24, 27) and dT in 1/12 study (16). Infants were
immunized with different DTaP vaccines and immunizationJuly 2021 | Volume 12 | Article 689394
Abu-Raya et al. Immune Responses to Immunizationsagainst Hib was part of DTaP formulations and conjugated to TT
in all studies (Table 1). Overall, risk of bias was low
(Supplementary Tables 2 and 3).
Data from 14/16 articles (10 studies) were received and
included in the meta-analysis (Table 1). Individual-participant
data integrity was confirmed for all studies.Frontiers in Immunology | www.frontiersin.org 4IgG levels against PT, FHA, PRN and FIM2/3 were
comparable pre-immunization in women who later received
Tdap in pregnancy compared to women who later did not
receive Tdap, (GMR 0.96; 95%CI 0.79-1.16), (GMR 0.98; 95%
CI 0.81-1.18), (GMR 1.07; 95%CI 0.84-1.37) and (GMR 1.05; 95%
CI 0.71-1.55), respectively (Figures 2A–D). Anti-PT, anti-FHA,FIGURE 1 | PRISMA IPD Flow Diagram. IPD, individual-participant data; GMR, geometric mean ratio. *In order to confirm data integrity, the main analysis for each
specific study was recapitulated and compared to the published data. Adapted from: "http://www.prisma-statement.org/Extensions/IndividualPatientData".July 2021 | Volume 12 | Article 689394
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Pentacel, Sanofi Pasteur or Infanrix, GSK
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Tdap group: Infanrix, GSK or TriHIBit,
Sanofi Pasteur or Pediarix®, GSK; 12-
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GSK or Pediarix®, GSK or Daptacel®
Sanofi Pasteur, or Pentacel®, Sanofi
Pasteur; 12-18 months
PT, FHA, PRN, FIM2/3,










Infanrix Hexa, GSK Biologicals; 2, 3, 4
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Infanrix Hexa, GSK Pentacel, Sanofi
Pediarix, GSK co-administered with with
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Sanofi at 11 months
PT, FHA, PRN, TT, DT,
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Prevenar-13®, Pfizer; 2, 4 months Neivac-
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Hib, MenC, SPN 1, 3, 4,
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Infanrix Hexa®, GSK Biologicals; 15
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Hexyon, Sanofi Pasteur at 8-12-16 weeks.
Synflorix, GSK at 8-16 weeks and 12
months.
Hexyon, Sanofi Pasteur at 15 months.
Synflorix, GSK at 12 months. Neivac-
C, Pfizer at 15 months.
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2 or 3 doses of DTaP-HepB-IPV/Hib
(Infanrix Hexa, GSK) co-administered with
PCV13 (Prevnar 13, Pfizer Inc.) at 2 and 4
N/A PT, FHA, PRN, TT, DT,
Hib, HBV, SPN 1, 3, 4,
6A, 6B, 7B, 9V, 14, 18C,
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Abu-Raya et al. Immune Responses to Immunizationsand anti-PRN IgG levels were significantly higher in women who
received Tdap in pregnancy post-immunization compared to
women who did not receive Tdap, (GMR 10.27; 95%CI 8.49-
12.41), (GMR 21.76; 95%CI 14.18-33.4), and (GMR 26.53; 95%CI
19.85-35.47), respectively (Figures 2A–C). At delivery, IgG levels
against PT, FHA, PRN and FIM2/3 were significantly higher in
women who received Tdap in pregnancy compared to women
who did not receive Tdap both in maternal and cord sera
(Figures 2A–D). These higher levels were still maintained pre-
primary immunization for anti-PT, anti-FHA, anti-PRN and
anti-FIM 2/3 IgG, (GMR 6.1; 95%CI 4.29-8.68), (GMR 10.09;
95%CI 6.64-15.34), (GMR 17.23; 95%CI 7.63-38.91) and (GMR
33.09; 95%CI 16.56-66.12), respectively (Figures 2A–D). Infants
of women immunized with Tdap in pregnancy had significantly
lower anti-PT IgG levels compared with infants of women who
did not receive Tdap in pregnancy post-primary and pre-booster
immunization with DTaP, (GMR 0.65; 95%CI 0.57-0.74), and
(GMR 0.67; 95% CI 0.56-0.8), respectively (Figure 2A). A trend
was noted post-booster immunization (GMR 0.76; 0.58-1.00)
(Figure 2A). Infants of women immunized with Tdap in
pregnancy had significantly lower anti-FHA IgG levelsFrontiers in Immunology | www.frontiersin.org 6compared with infants of women who did not receive Tdap in
pregnancy post-primary, pre-booster and post-booster
immunization with DTaP, (GMR 0.68; 95%CI 0.53-0.87),
(GMR 0.61; 95% CI 0.49-0.77), and (GMR 0.72; 95% CI 0.61-
0.84), respectively (Figure 2B). Infants of women immunized
with Tdap in pregnancy had significantly lower anti-PRN IgG
levels compared with infants of women who did not receive
Tdap in pregnancy post-pr imary and pre-booster
immunization with DTaP, (GMR 0.65; 95%CI 0.58-0.72), and
(GMR 0.57; 95% CI 0.46-0.72), respectively (Figure 2C).
Infants of women immunized with Tdap in pregnancy had
significantly lower anti- FIM2/3 IgG levels compared with
infants of women who did not receive Tdap in pregnancy
post-primary and post-booster immunization with DTaP,
(GMR 0.41; 95%CI 0.32-0.52), and (GMR 0.53; 95% CI 0.29-
0.96), respectively (Figure 2D).
The GMRs of IgG against PT, FHA and PRN pre-
immunization in pregnancy and at delivery in women
immunized in pregnancy vs. unimmunized women and their
infants stratified by type of vaccine administered in pregnancy
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months; or 3 and 5 months; or 2, 4 and 6
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according to the different countries’
routine primary immunization schedules
19A, 19F, 23F; Polio













DtaP5-IPV-Hib Pediacel, Sanofi Pasteur or
DtaP3-IPV-Hib (Infanrix-IPV-Hib; GSK) at
2, 3 and 4 months of age. Prevenar 13
(Pfizer) at 2 and 4 months of age
N/A PT, FHA, PRN, TT, DT,
Hib, SPN 1, 3, 4, 6A, 6B,











Infanrix Hexa, GSK; Prevenar 13, Wyeth;
At 6 weeks, 4 months and 6 months of
age
Menitorix, GSK; at 12 months of age PT, FHA, PRN, TT, DT,
Hib, SPN 1, 3, 4, 6A, 6B,
7B, 9V, 14, 18C, 19A,
19F, 23F. Polio (types 1,
2, 3), MenC, measles,
mumps and rubellaJuly 2021 | V*Included in the individual-participant data meta-analysis.
**The original study randomized infants to receive or not Bacillus Calmette–Guérin at birth. For the purpose of this meta-analysis, women were not randomized to receive Tdap or
not in pregnancy.
***The original study randomized infants to receive different immunization schedules. For the purpose of this meta-analysis, women were not randomized to receive Tdap or
not in pregnancy.
****Vaccination schedule per published articles and their composition is:
Boostrix: TT (5 Lf), DT (2.5 Lf), PT (8 mcg), FHA (8 mcg), PRN (2.5 mcg), Adacel: TT (5 Lf). DT (2 Lf), PT (2.5 mcg), FHA (5 mcg), PRN (3 mcg), FIM2/3 (5 mcg). Repevax: TT (≥20 IU), DT (≥2
IU), PT (2.5 mcg), FHA (5 mcg), PRN (3 mcg), FIM2/3 (5 mcg), polio virus type 1 (40 D antigen units), polio virus type 2 (8 D antigen units), polio virus type 3 (32 D antigen units). Infanrix
Hexa: TT (10 Lf), DT (25 Lf), PT (25 mcg), FHA (25 mcg), PRN (8 mcg), HBsAg (10 mcg), polio virus type 1 (40 D antigen units), polio virus type 2 (8 D antigen units), polio virus type 3 (32 D
antigen units), Hib (10 mcg). Pediacel: TT (5 Lf), DT (15 Lf), PT (20 mcg), FHA (20 mcg), PRN (3 mcg), FIM2/3 (5 mcg), polio virus type 1 (40 D antigen units), polio virus type 2 (8 D antigen
units), polio virus type 3 (32 D antigen units), Pediarix: TT (10 Lf), DT (25 Lf), PT (25 mcg), FHA (25 mcg), PRN (8 mcg), polio virus type 1 (40 D antigen units), polio virus type 2 (8 D antigen
units), polio virus type 3 (32 D antigen units), HBsAg (10 mcg). Pentacel: TT (5 Lf), DT (15 Lf), PT (20 mcg), FHA (20 mcg), PRN (3 mcg), FIM2/3 (5 mcg), polio virus type 1 (40 D antigen
units), polio virus type 2 (8 D antigen units), polio virus type 3 (32 D antigen units), Hib (10 mcg). Hexyon: TT (≥40 IU), DT (≥20 IU), PT (25 mcg), FHA (25 mcg), polio virus type 1 (40 D
antigen units), polio virus type 2 (8 D antigen units), polio virus type 3 (32 D antigen units), HBsAg (10 mcg), Hib (12 mcg). Daptacel: TT (5 Lf), DT (15 Lf), PT (10 mcg), FHA (5 mcg), PRN (3
mcg), FIM2/3 (5 mcg). Hiberix: Hib (10 mcg). ActHIB: Hib (10 mcg).
US, United States; Tdap, tetanus-diphtheria-acellular-pertussis; GSK, GlaxoSmithKline; PT, pertussis toxin; FHA, filamentous hemagglutinin; PRN, pertactin; FIM2/3, fimbriae 2/3; TT,
tetanus toxoid; DT, diphtheria toxoid; HBV, Hepatitis B virus; UK, United Kingdom; WG, weeks gestation; Hib, Haemophilus influenzae b; MenC, meningococcal C; SPN, Streptococcus
pneumoniae; N/Av, not available; N/A, not applicable. IPV, inactivated polio virus; IU, International Unit; HBsAg,hepatitis B surface antigen.olume 12 | Article 689394
Abu-Raya et al. Immune Responses to ImmunizationsAs Tdap vaccines administered in pregnancy also include
tetanus antigens, the GMRs of anti-TT IgG in the groups of
women immunized with Tdap vs. unimmunized in pregnancy and
their infants before and after receipt of DTaP in infancy were
determined. Anti-TT IgG levels were comparable pre-
immunization in women who later received Tdap in pregnancy
compared to women who later did not receive Tdap, TT or dT
vaccines in pregnancy (Figure 3A). Anti-TT IgG levels were
higher in women who received Tdap in pregnancy post-
immunization compared to women who did not receive Tdap,
TT or dT vaccines in pregnancy (Figure 3A).Anti-TT IgG levels
were higher at birth, pre-primary immunization and post-booster
immunization with DTaP, in infants born to women immunized
with Tdap in pregnancy compared with infants of women who did
not receive Tdap, TT or dT vaccines in pregnancy, (GMR 4.53;
95%CI 1.55-13.52), (GMR 5.46; 95% CI 3.98-7.49), and (GMR
1.59; 95% CI 1.04-2.42), respectively (Figure 3A).
Tdap vaccines administered in pregnancy also include
diphtheria antigens, thus the GMRs of anti-DT IgG in the
groups of women immunized with Tdap vs. unimmunized in
pregnancy and their infants before and after receipt of DTaP inFrontiers in Immunology | www.frontiersin.org 7infancy were also sought. Anti-DT IgG levels were comparable
pre-immunization in women who later received Tdap in
pregnancy compared to women who later did not receive Tdap
or dT (Figure 3B). Anti-DT IgG levels were higher in women
who received Tdap in pregnancy post-immunization and at
delivery compared to women who did not receive Tdap or dT.
Anti-DT IgG levels were higher in infants born to Tdap-
immunized women at birth and pre-primary immunization
(Figure 3B). Infants of women immunized with Tdap in
pregnancy had significantly lower anti-DT IgG levels
compared with infants of women who did not receive Tdap or
dT in pregnancy post-primary, pre-booster and post-booster
immunization with DTaP, (GMR 0.63; 95%CI 0.5-0.79), (GMR
0.68; 95% CI 0.54-0.87), and (GMR 0.81; 95% CI 0.71-0.91),
respectively (Figure 3B).
As Tdap vaccines administered in pregnancy include tetanus
antigens, the GMRs of anti-PRP IgG in the groups of women
immunized with Tdap vs. unimmunized in pregnancy and their
infants before andafter receipt ofHib vaccines conjugated toTTwere
determined. Anti-PRP IgG levels were not significantly different in




















































































































































































































































































































































FIGURE 2 | Antibody responses to pertussis antigens. Geometric mean ratio (GMR) of (A) anti-pertussis toxin (PT). (B) anti-filamentous haemagglutinin (FHA),
(C) anti-pertactin (PRN), and (D) anti-fimbria 2/3 (FIM2/3) IgG levels in women immunized with tetanus-diphtheria-acellular-pertussis (Tdap) versus women who did
not receive Tdap in pregnancy pre-immunization, post-immunization and at delivery; in infants born to women immunized with Tdap versus infants of women not
immunized with Tdap in pregnancy pre-primary, post-primary, pre-booster and post-booster immunization with diphtheria-tetanus-acellular-pertussis. For FIM2/3,
GMR was not computed post-immunization in pregnancy and pre-booster immunization in infancy, as data were available for one study on these time points
precluding meta-analysis. Vertical blue lines indicate the GMR with the 95% confidence interval. Horizontal black line indicates a GMR of 1. The numbers available for
meta-analysis are indicated (n). GMR results displayed are derived from mixed-effects models. Pre-imm, pre-immunization; Post-imm, post-immunization; Mat,
maternal; Pre-prim, pre-primary; Post-prim, post-primary; Pre-boost, pre-booster; Post-boost, post-booster.July 2021 | Volume 12 | Article 689394
Abu-Raya et al. Immune Responses to Immunizationscomparedwith infants ofwomenwhodidnot receiveTdap,TTordT
vaccines in pregnancy at all-time points (Figure 4A).
Given that Tdap vaccines administered in pregnancy include
diphtheria antigens, the GMRs of anti-SPN IgG in the groups of
infants born to women immunized with Tdap vs. unimmunized
in pregnancy after receipt of pneumococcal vaccines conjugated
to DT were also computed. Anti-SPN IgG levels were
significantly lower in infants born to women immunized with
Tdap in pregnancy post-primary immunization with PCV13
compared with infants of women who did not receive Tdap or
dT vaccines in pregnancy for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V,
18C, 19A, 19F, 23F with a reduction ranged from 15 to
35% (Figure 4B).
In order to provide insights whether the changes in antigen-
specific GMRs following Tdap immunization in pregnancy affect
protection from infections in women and their infants,
seroprotection rates against diseases for which there are
correlates of protection (tetanus, diphtheria, Hib, IPD) were
explored. Nearly 93% of women had seroprotective antibody
levels against tetanus disease pre-immunization (Figure 5A).
This rate increased to nearly 100% at birth in women immunized
with Tdap during pregnancy and in cord of pregnant women
immunized and unimmunized with Tdap, TT or dT vaccines in
pregnancy (Figure 5A). Infants of women immunized with Tdap
in pregnancy had significantly higher seroprotection rates
against tetanus pre-primary and pre-booster immunization
compared with infants of women unimmunized with Tdap, TT
or dT vaccines in pregnancy, 98% (647/662) vs 90.1% (327/363),
and 92% (563/599) vs 87% (227/261), p<0.001, p=0.001,
respectively (Figure 5A). Infants of women immunized withFrontiers in Immunology | www.frontiersin.org 8Tdap in pregnancy had comparable high seroprotection
rate post-primary and post-booster immunization compared
with infants of women unimmunized with Tdap, TT or dT
vaccines in pregnancy, 99% (946/947) vs 100% (531/531), and
99% (618/619) vs 100% (211/211), respectively, p=1 for both
comparisons (Figure 5A).
In addition, the seroprotection rates against diphtheria disease
in the groups of women immunized with Tdap vs. unimmunized
in pregnancy and their infants before and after receipt of DTaP in
infancy were also determined. Nearly 60% of pregnant women
had seroprotection antibody levels against diphtheria disease
pre-immunization (Figure 5B). Seroprotection rates against
diphtheria disease were significantly higher in women
immunized with Tdap in pregnancy post-immunization and at
birth compared with women who did not receive Tdap or dT
vaccine in pregnancy (Figure 5B). Infants of women immunized
with Tdap in pregnancy had significantly higher seroprotection
rates against diphtheria pre-primary immunization and
significantly lower seroprotection rates post-primary
immunization compared with infants of women who did not
receive Tdap or dT vaccines in pregnancy, 78% (517/663) vs 35%
(142/409) and 90% (843/937) vs 98% (566/579), all p<0.001
(Figure 5B). Nearly 60% (420/701) of infants born to women
immunized with Tdap in pregnancy had seroprotective anti-DT
levels pre-booster immunization, increasing to 99% (286/288)
post-booster immunization (Figure 5B).
The seroprotection rates against Hib in the groups of women
immunized with Tdap vs. unimmunized in pregnancy and their
infants before and after receipt of Hib vaccines conjugated to TT,
were calculated applying both short and long term cut-offs forTABLE 2 | Geometric mean ratio of anti-Bordetella pertussis IgG levels in women immunized with tetanus-diphtheria-acellular-pertussis (Tdap) versus women who did
not receive Tdap in pregnancy and their infants stratified by type of vaccine administered in pregnancy.
Geometric mean ratio (95% CI, n)
Pertussis toxin Filamentous hemagglutinin Pertactin
Adacel in pregnancy
Pregnancy*
Pre-immunization 1.17 (0.94-1.45, 409) 1.07 (0.83-1.38, 419) 0.96 (0.58-1.61, 417)
Delivery
Maternal 5.16 (2.93-9.1, 411) 10.11 (7.54-13.56, 404) 22.91 (16.66-31.51, 403)
Cord 4.47 (2.91-6.86, 386) 6.57 (3.3-13.1, 395) 18.32 (9.08-36.96, 398)
Infancy**
Pre-primary 4.14 (2.95-5.82, 341) 6.96 (2.38-20.36, 361) 12.49 (5.84-26.68, 361)
Post-primary 0.83 (0.68-1, 338) 0.69 (0.47-1, 338) 0.66 (0.53-0.82, 334)
Post-booster 0.76 (0.62-0.94, 342) 0.75 (0.59-0.96, 343) 1.11 (0.9-1.37, 346)
Boostrix in pregnancy
Pregnancy*
Pre-immunization 0.86 (0.64-1.15, 723) 0.9 (0.7-1.16, 727) 1.01 (0.81-1.27, 726)
Delivery
Maternal 2.75 (0.27-27.89, 197) 4.07 (0.42-39.16, 145) 12.42 (2.54-60.71, 200)
Cord 8.49 (6.81-10.57, 771) 14.31 (8.96-22.85, 775) 20.67 (14.2-30.09, 772)
Infancy
Pre-primary 7.01 (4.42-11.13, 563) 11.68 (7.46-18.28, 566) 17.45 (11.94-25.52, 616)
Post-primary 0.58 (0.51-0.66, 843) 0.67 (0.42-1.07, 365) 0.6 (0.51-0.7, 734)
Pre-booster 0.59 (0.5-0.69, 576) 0.61 (0.41-0.9, 586) 0.47 (0.35-0.63, 481)
Post-booster 0.78 (0.37-1.65, 288) 0.77 (0.49-1.21, 286) 0.8 (0.52-1.22, 174)July 2021 | VoGiven that Fimbria antigens exists only in Adacel, separate analyses were not performed as the analyses presented in Figure 2D were restricted to women who received Adacel and their infants.
*Post-immunization in pregnancy analyses were not performed, as model fitting was not feasible due to the small number of studies eligible for inclusion.
**Pre-booster immunization in infancy analyses were not performed, as model fitting was not feasible due to the small number of studies eligible for inclusion.lume 12 | Article 689394
















































































































































































Pregnancy             Delivery                       Infancy
FIGURE 3 | (A) Antibody responses to tetanus-toxoid (TT). Geometric mean ratio (GMR) of anti-TT IgG levels in women immunized with tetanus-diphtheria-
acellular-pertussis (Tdap) versus women who did not receive Tdap or diphtheria and tetanus toxoids (dT) or TT vaccine in pregnancy pre-immunization, post-
immunization and at delivery; in infants born to women immunized Tdap versus infants of women not immunized with Tdap dT, or TT vaccine in pregnancy pre-
primary, post-primary, pre-booster and post-booster immunization with diphtheria-tetanus-acellular-pertussis vaccine. (B) Antibody responses to diphtheria-
toxoid (DT). GMR of anti-DT IgG levels in women immunized with Tdap versus women who did not receive Tdap or dT vaccine in pregnancy pre-immunization,
post-immunization and at delivery; in infants born to women immunized Tdap versus infants of women not immunized with Tdap or dT vaccine in pregnancy
pre-primary, post-primary, pre-booster and post-booster immunization with diphtheria-tetanus-acellular-pertussis vaccine. Vertical blue lines indicate the GMR
with the 95% confidence interval. Horizontal black line indicates a GMR of 1. The numbers available for meta-analysis are indicated (n). GMR results displayed
are derived from mixed-effects models. Pre-imm, pre-immunization; Post-imm, post-immunization; Mat, maternal; Pre-prim, pre-primary; Post-prim, post-
primary; Pre-boost, pre-booster; Post-boost, post-booster.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 6893949
Abu-Raya et al. Immune Responses to Immunizationsprotection. Nearly 85% of pregnant women had protective
antibody levels against Hib using the short term cut off for
protection pre-immunization (Figure 6A). In addition, infants of
women immunized with Tdap in pregnancy compared withFrontiers in Immunology | www.frontiersin.org 10infants of women who did not receive Tdap, TT or dT
vaccines in pregnancy had significantly higher seroprotection
rates against Hib post-primary immunization 86% (471/547) vs



















































































































































































 Post primary immunization with PCV 13 
FIGURE 4 | (A) Antibody responses to Haemophilus influenza type b (polyribosylribitol phosphate [PRP]). Geometric mean ratio (GMR) of anti-PRP IgG levels in
women immunized with tetanus-diphtheria-acellular-pertussis (Tdap) versus women who did not receive Tdap or diphtheria and tetanus toxoids (dT) or TT vaccine in
pregnancy pre-immunization; in infants born to women immunized Tdap versus infants of women not immunized with Tdap, dT, or TT vaccine in pregnancy pre-
primary, post-primary, pre-booster and post-booster immunization with diphtheria-tetanus-acellular-pertussis-Hib vaccine. (B) Antibody responses to Streptococcus
pneumoniae (SPN). GMR of anti-SPN IgG levels in infants born to women immunized with Tdap compared with infants of women who did not receive Tdap or dT
vaccine in pregnancy after their primary immunization with pneumococcal conjugate vaccine 13 (PCV 13). Vertical blue lines indicate the GMR with the 95%
confidence interval. Horizontal black line indicates a GMR of 1. The numbers available for meta-analysis are indicated (n). GMR results displayed are derived from
mixed-effects models. Pre-imm, pre-immunization; Pre-prim, pre-primary; Post-prim, post-primary; Pre-boost, pre-booster; Post-boost, post-booster; S, Serotype.July 2021 | Volume 12 | Article 689394




























































































































































































































































FIGURE 5 | (A) Seroprotection rates against tetanus diseases. Rates of participants with anti–tetanus toxoid (TT) IgG ≥0.1 IU/mL in women immunized with tetanus-
diphtheria-acellular pertussis (Tdap) versus women who did not receive Tdap, diphtheria and tetanus toxoids (dT), or TT vaccine in pregnancy pre-immunization,
post-immunization and at delivery; in infants born to women immunized Tdap versus infants of women not immunized with Tdap, dT or TT vaccine in pregnancy pre-
primary, post-primary, pre-booster and post-booster immunization with diphtheria-tetanus-acellular pertussis vaccine (*comparisons with p-values <0.05). P-values:
Pre-imm: p=0.806; Post-imm: p = 0.001; Maternal: p<0.001; Cord: p = 0.754; Pre-prim: p<0.001;Post-prim: p =1; Pre-boost: p=0.001;Post-boost: p =1.
(B) Seroprotection rates against diphtheria diseases. Rates of participants with anti-DT IgG ≥0.1 IU/mL in women immunized with tetanus-diphtheria-acellular
pertussis (Tdap) versus women who did not receive Tdap or dT vaccine in pregnancy pre-immunization, post-immunization and at delivery; in infants born to women
immunized Tdap versus infants of women not immunized with Tdap or dT vaccine in pregnancy pre-primary, post-primary, pre-booster and post-booster
immunization with diphtheria-tetanus-acellular pertussis vaccine (*comparisons with p-values < 0.05). P-values: Pre-imm: p=0.045; Post-imm: p<0.001; Maternal:
p<0.001; Cord: p<0.001; Pre-prim: p<0.001; Post-prim: p<0.001; Pre-boost: p=0.116; Post-boost: p=0.863. Seroprotection rates were compared using the chi-
squared test. Pre-imm, pre-immunization; Post-imm, post-immunization; Pre-prim, pre-primary; Post-prim, post-primary; Pre-boost, pre-booster; Post-boos, post-
booster; I, immunized; U, Unimmunized. Absolute numbers are shown in the bottom and percentages in the top of the bars.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 68939411
Abu-Raya et al. Immune Responses to Immunizations(397/529) vs 73% (172/235), and post-booster immunization
97% (515/533) vs 96% (238/248), p=0.001, p=0.651, p=0.801,
respectively, using the cut off of short term protection
(Figure 6A). Applying the cut-off of long-term protection
against Hib, infants of women immunized with Tdap in
pregnancy had significantly higher seroprotection rates against
Hib post-primary immunization 62% (337/547) vs 49% (121/
247), pre-booster immunization 35% (186/529) vs 26% (62/235),
and post-booster immunization 90% (481/533) vs 83% (207/
248), compared with infants of women who did not receive Tdap,
TT or dT vaccines in pregnancy, p=0.001, p=0.021, p=0.009,
respectively (Figure 6B).
Seroprotection rates against SPN following primary
immunization with PCV conjugated to DT were also explored.
Post-primary immunization with PCV-13, seroprotection rates
against 5/13 SPN serotypes were significantly lower in infants of
women immunized with Tdap in pregnancy compared with
infants of women who did not receive Tdap or dT vaccines in
pregnancy, SPN5 85% (268/316) vs 93% (266/287), p=0.004;
SPN6B 72% (234/323) vs 82% (237/290),p=0.009; SPN9V 88%
(285/323) vs 94% (273/290),p=0.016; SPN19A 92% (281/306) vs
96% (270/281), p=0.048; SPN23F 76% (243/321) vs 85% (247/
289), p=0.003, (Figure 7).DISCUSSION
This unique, large (n=1583), international and longitudinal
mother-infant meta-analysis of individual-participant data from
10 studies has enabled us to clearly quantify the magnitude of
immune response to Tdap vaccine in pregnant women and their
infants at delivery and pre-primary immunization. We also were
able to quantify the reduction in immune responses to pertussis,
diphtheria and 12/13 SPN serotypes following primary
immunization in infants born to women immunized with Tdap
in pregnancy. In addition, we showed that for some antigens this
persisted beyond booster infant immunization. Moreover, this
reduction in antibody levels resulted in lower seroprotection rates
for 5/13 SPN serotypes and for diphtheria after primary
immunization. In contrast, enhanced immune responses to
tetanus and Hib vaccines conjugated to TT were observed in
infants born to women immunized with Tdap in pregnancy. These
data have important implications in establishing the effect of Tdap
immunization in pregnancy on the antibody immune responses to
different vaccine antigens in infancy and inform policy makers in
countries where programs of immunization against pertussis in
pregnancy have been recommended or being considered.
Studies prior to the implementation of immunization against
pertussis in pregnancy suggested that higher pre-existing
maternally derived antibody levels could have a suppressive
effect on infants’ immune responses to primary immunization
against pertussis and other antigens (10–13). This meta-analysis
provides further support to these findings in the era of Tdap
immunization in pregnancy and also extends these findings to
booster immunization. This reduction might potentially put
infants born to women immunized against pertussis inFrontiers in Immunology | www.frontiersin.org 12pregnancy at increased risk for pertussis disease later in their
infancy. However, current surveillance data do not indicate that
this reduction in anti-B. pertussis antibody levels is clinically
relevant. This is because the incidence of pertussis disease in
infants after primary and booster immunization did not
significantly increase after the introduction of a maternal
pertussis immunization program in the UK and was at 2.2 per
100,000 in infants 1-4 years of age (33). In a study conducted in
the US between 2010-2015, effectiveness of immunization
against pertussis in pregnancy was 66% among infants who
received 3 primary immunization doses against pertussis and
aged <1 year (34). However, additional disease burden data are
needed to definitely assess the true clinical significance of such
reduction as the cohort of infants born to pertussis-vaccinated
women is increasing (35).
The general mechanism of this modification of immune
responses has not been fully investigated. Inhibition of B cell
activation through the FcgRIIB on B cells has been proposed.
Specifically, vaccine antigen–antibody complexes cross-link the
B-cell receptor with the FcgRIIB, thus inhibiting antigen specific
B-cell activation (36). It was recently shown in an influenza mice
model that inhibition of immune response to immunization
following influenza immunization in pregnancy was antigen-
specific and correlated with maternal antibodies in a dose-
dependent manner and was associated with reduction in the
number of germinal center B cells that differentiate into plasma
cells and memory B cells (37). This might potentially explain the
durable effect of immunization in pregnancy on booster
immunization in infancy. Inhibition of B cell via epitope
masking is another suggested mechanism. In this mechanism,
the B cell epitopes on a vaccine antigen(s) are covered by
antibodies and thus are not recognized by B cells (38).
However, this does not explain the inhibitory effect observed
following booster immunization.
As current formulations of Tdap vaccines used in pregnancy
also include tetanus toxoids and diphtheria toxoids, infants’
immune responses to TT and DT components of vaccines and
vaccines conjugated these toxoids as carrier proteins (e.g. Hib
vaccine, and PCVs) might also be modified. In this large meta-
analysis, we were able to accurately quantify the reduced immune
responses to diphtheria and some SPN serotypes in infants born to
women immunized with Tdap in pregnancy after primary and
booster immunization, and to show lower seroprotection rates for
diphtheria and some SPN serotypes after primary immunization.
This might increase the risk of infection with these pathogens in
infants born to women immunized with Tdap in pregnancy.
Although diphtheria disease incidence has decreased since the
implementation of 3 doses of DT-containing vaccines, outbreaks
do still occur, especially in low-middle income countries and
among unimmunized subjects (39). In high-income countries,
diphtheria is a rare disease (40). To the best of our knowledge, the
clinical significance of the reduction of seroprotection rates against
SPN has not yet been published. While anti-SPN >0.35 ug/ml cut-
off is used for licensure of pneumococcal vaccines, some studies
showed that SPN correlates of protection are serotype-specific,
and are different for protection against disease versus colonization,July 2021 | Volume 12 | Article 689394




























































































































































































































FIGURE 6 | (A) Short-term seroprotection rates against haemophilus influenzae type b (Hib) disease. Rates of subjects with anti–polyribosylribitol phosphate (PRP) IgG
≥0.15 mcg/ml in women immunized with tetanus-diphtheria-acellular pertussis (Tdap) versus women who did not receive Tdap vaccine, diphtheria and tetanus toxoids
(dT) or tetanus-toxoid (TT) vaccine in pregnancy pre- immunization and at delivery; in infants born to women immunized Tdap versus infants of women not immunized
with Tdap, dT or TT vaccine in pregnancy pre-primary, post-primary, pre-booster and post-booster immunization with diphtheria-tetanus-acellular-pertussis-Hib vaccine
(*comparisons where p-values <0.05). P-values: Pre-imm: p= 0.707; Maternal: p<0.001; Cord: p=0.765; Pre-prim: p<0.001; Post-prim: p= 0.001; Pre-boost: p=
0.651; Post-boost:p=0.801. (B) Long-term seroprotection rates against Hib disease. Rates of subjects with anti–PRP IgG ≥1 mcg/ml in women immunized with Tdap
versus women who did not receive Tdap, dT or TT vaccine in pregnancy pre- immunization and at delivery; in infants born to women immunized Tdap versus infants of
women not immunized with Tdap, dT or TT vaccine in pregnancy pre-primary, post-primary, pre-booster and post-booster immunization with diphtheria-tetanus-acellular-
pertussis-Hib vaccine (*comparisons where p-values <0.05). P-values: Pre-imm: p= 0.705; Maternal: p= 0.189; Cord: p=1; Pre-prim: p<0.001; Post-prim: p= 0.001;
Pre-boost: p= 0.021; Post-boost: p=0.009. Seroprotection rates were compared using the chi-squared test. Pre-imm, pre-immunization; Pre-prim, pre-primary; Post-
prim, post-primary; Pre-boost, pre-booster; Post-boos, post-booster; I, immunized; U, Unimmunized. Absolute numbers are shown in the bottom and percentages in the
top of the bars.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 68939413
Abu-Raya et al. Immune Responses to Immunizationswhich further complicates the interpretation of immunogenicity
data we present in this study (41, 42). In addition, there have been
changes in the pneumococcal immunization programs in different
countries and these should be considered in the setting of
immunization with Tdap in pregnancy. For example, in the UK,
PCV primary immunization has been reduced from 2 primary
doses followed by a booster dose to a one primary dose followed by
a booster dose (43).
The association between Tdap administration in pregnancy and
reduced immune response to immunization with PCV13 could be
mediated via anti-DT antibodies that are transferred to infants,
because each of the 13 polysaccharides included in PCV13 is
conjugated to CRM197 (a non-toxic mutant of DT). This is
supported by the findings that maternal pre-existing anti-DT
antibody levels were associated with lower immune response to
serotypes 4, 6B and 9V after immunization with PCV7, and lower
response to 19F (the only serotype conjugated to DT) after
immunization with PCV10 (22). Our meta-analysis also showed
enhanced immune response to tetanus and Hib vaccines conjugated
to TT in infants born to women immunized with Tdap in
pregnancy. Studies outside the setting of maternal immunization
showed that immunization with Hib vaccine conjugated to TT was
associated with higher anti-PRP levels when given concomitantly
withmeningococcal serogroup C polysaccharide vaccine conjugated
to TT, supporting the enhancement of immunogenicity of Hib
vaccines conjugated to TT (44).
This meta-analysis has a number of strengths. This is the first
detailed and longitudinal analysis of the largest number of
samples combined to establish the effect of immunization
against pertussis in pregnancy on immune response to
different vaccine antigens, routinely given to infants worldwide.
Given the individual-participant nature of this meta-analysis, we
were able to adjust for co-variates that could have affected theFrontiers in Immunology | www.frontiersin.org 14immune responses and to determine seroprotection rates for
some vaccine-preventable diseases. Our study has some
limitations. Most studies were conducted in high-income
countries, thus data are less relevant to countries where whole-
cell pertussis is being used for infants’ immunizations. As we
investigated immune responses, our results should be interpreted
in the context of clinical data.
Our meta-analysis quantified the effect of Tdap immunization
in pregnancy on antigen-specific antibody responses to
immunizations in infancy and showed inhibition of antibody
responses to pertussis, diphtheria and some SPN serotypes.
Continuous and enhanced surveillance is needed for multiple
diseases (pertussis, diphtheria and IPD). Exploring the
mechanism(s) of this modification of immune responses is
critical and will help in informing design and use of futures
vaccines to be used in pregnancy (e.g. conjugated group B
Streptococcus and respiratory syncytial virus vaccines).DATA AVAILABILITY STATEMENT
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